TY - JOUR KW - Adjuvants, Immunologic KW - Animals KW - Antibody-Producing Cells KW - Concanavalin A KW - Cytokines KW - Erythrocytes KW - Humans KW - Immunoglobulin M KW - Immunosuppressive Agents KW - Leukocytes, Mononuclear KW - Mice KW - Sheep KW - Stimulation, Chemical KW - Structure-Activity Relationship KW - Thalidomide KW - Tumor Necrosis Factor-alpha AU - Shannon E J AU - Morales M J AU - Sandoval F AB -

Thalidomide, which has a long history of tragedy because of its ability to cause severe birth defects, is very effective in alleviating erythema nodosum leprosum in leprosy patients and aphthous ulcers in AIDS patients. The causes of these inflammatory diseases and the mechanism by which thalidomide diminishes them are unknown. It has been suggested that modulation of the immune response plays an important role. We found that thalidomide exerts immunomodulatory activity in three bioassays. It suppresses an IgM plaque forming cell response in mice injected with sheep erythrocytes: it inhibits TNF-alpha production by LPS stimulated human mononuclear cells: and it enhances IL-2 production by Con-A stimulated human mononuclear cells. We employed these bioassays to compare the activity of 15 analogs of thalidomide with thalidomide itself. Eight of the compounds were derivatives of the glutarimide moiety of thalidomide and the others were phthalimide or derivatives of the phthalimide moiety of thalidomide. N-hydroxyphthalimide, a simple derivative of phthalimide, was more effective than thalidomide and was also the most effective of the compounds assayed in suppressing the IgM plaque and TNF-alpha responses, but it did not enhance the IL-2 response, instead, it significantly suppressed it.

BT - Immunopharmacology C1 - http://www.ncbi.nlm.nih.gov/pubmed/9043933?dopt=Abstract DA - 1997 Jan DO - 10.1016/s0162-3109(96)00149-x IS - 3 J2 - Immunopharmacology LA - eng N2 -

Thalidomide, which has a long history of tragedy because of its ability to cause severe birth defects, is very effective in alleviating erythema nodosum leprosum in leprosy patients and aphthous ulcers in AIDS patients. The causes of these inflammatory diseases and the mechanism by which thalidomide diminishes them are unknown. It has been suggested that modulation of the immune response plays an important role. We found that thalidomide exerts immunomodulatory activity in three bioassays. It suppresses an IgM plaque forming cell response in mice injected with sheep erythrocytes: it inhibits TNF-alpha production by LPS stimulated human mononuclear cells: and it enhances IL-2 production by Con-A stimulated human mononuclear cells. We employed these bioassays to compare the activity of 15 analogs of thalidomide with thalidomide itself. Eight of the compounds were derivatives of the glutarimide moiety of thalidomide and the others were phthalimide or derivatives of the phthalimide moiety of thalidomide. N-hydroxyphthalimide, a simple derivative of phthalimide, was more effective than thalidomide and was also the most effective of the compounds assayed in suppressing the IgM plaque and TNF-alpha responses, but it did not enhance the IL-2 response, instead, it significantly suppressed it.

PY - 1997 SP - 203 EP - 12 T2 - Immunopharmacology TI - Immunomodulatory assays to study structure-activity relationships of thalidomide. VL - 35 SN - 0162-3109 ER -